LJLuiz Carlos da Costa Junior

Luiz Carlos da Costa Junior

*This is an algorithmically generated author record based on publicly available information.

Luiz Carlos da Costa Junior has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tacrolimus Concentration/Dose Ratio in Hematopoietic Cell Transplantation Recipients: An Exploratory Study of Metabolizer Phenotyping and Clinical Outcomes

    by Luiz Carlos da Costa‐Junior, Rita de Cássia Barbosa da Silva Tavares, Marina Izu, Simone Cunha Maradei, Maria Claudia Rodrigues Moreira, Marta Colares Nogueira, Décio Lerner, Teresa de Souza Fernandez, Paulo Caleb Júnior Lima Santos

    Tacrolimus pharmacokinetics shows wide interindividual variability after allogeneic hematopoietic cell transplantation (HCT), potentially influencing both effectiveness and toxicity. The concentration‐to‐dose (C/D) ratio has been proposed as a simple surrogate marker of tacrolimus metabolism, enabling patient stratification into fast or slow metabolizers. In this retrospective single‐center study, we evaluated the clinical applicability of the C/D ratio in 71 HCT recipients treated between 2014 and 2023. Fast metabolizers (< 420 ng/mL·1/mg/kg) required higher tacrolimus doses and exhibited lower trough concentrations compared with slow metabolizers (≥ 420). Slow metabolizers had a higher risk of moderate‐to‐severe acute kidney injury (AKI) within 21 days after starting tacrolimus (HR 3.72; 95% CI 1.19–11.61; p = 0.024). In contrast, fast metabolizers showed a trend toward increased incidence of acute graft‐versus‐host disease (aGVHD) (HR 1.91; 95% CI 0.93–3.92) and an almost universal need for dose escalation (96.8%). Tacrolimus metabolism exerts opposing effects on renal safety and immunosuppressive effectiveness, with faster clearance predisposing to immune activation and slower clearance to early AKI. The C/D ratio provides an early pharmacokinetic snapshot capable of anticipating individual exposure patterns and may serve as a practical tool to guide proactive dosing and optimize the balance between effectiveness and safety in HCT recipients.

  • Open Access

    Early Acute Kidney Injury in Allogeneic Hematopoietic Cell Transplantation: Incidence, Severity, and Associated Factors in a 634‐Recipient Cohort

    by Luiz Carlos da Costa‐Junior, Rita de Cássia Barbosa da Silva Tavares, Marina Izu, Simone Cunha Maradei, Maria Claudia Rodrigues Moreira, Marta Colares Nogueira, Décio Lerner, Fabrício Guimarães Bino, Patrícia Moriel, Teresa de Souza Fernandez, et al.

    Background: Acute kidney injury (AKI) is a frequent and clinically relevant complication in allogeneic hematopoietic cell transplantation (HCT) recipients, particularly during the early post‐HCT period. Although AKI has been extensively reported in long‐term follow‐up studies, data focusing on the initial hospitalization phase remain limited, despite its potential impact on subsequent clinical outcomes. Objective: To evaluate the incidence, severity, and clinical and transplant‐related determinants of AKI during the first 3 weeks after allogeneic HCT. Methods: We conducted a retrospective cohort study including 634 consecutive recipients undergoing allogeneic HCT between 2002 and 2023. AKI was defined according to KDIGO criteria and assessed from day +1 to day +21. Cumulative incidence was estimated, and associations were evaluated using Cox proportional hazards models. Pre‐AKI exposure to calcineurin inhibitors was analyzed. Results: By day 21, AKI occurred in 346 patients (55%), and 27% of cases reached KDIGO stages 2–3. Median time to AKI was 12 days, with earlier onset among stage 3 events (median 5 days). In multivariable analysis, AST > 40 U/L was independently associated with an increased risk of any‐stage AKI (HR 1.58, 95% CI 1.17–2.12; p = 0.003), whereas albumin > 3.5 g/dL was protective (HR 0.56, 95% CI 0.44–0.71; p < 0.001). Severe AKI was associated with AST > 40 U/L (HR 1.93, 95% CI 1.08–3.44; p = 0.025) and year of transplantation, with higher risk observed in earlier categories (2002–2008: HR 3.68, 95% CI 1.75–7.72; p < 0.001), while higher albumin levels remained inversely associated (HR 0.42, 95% CI 0.26–0.70; p < 0.001). Higher pre‐AKI cyclosporine trough levels (HR 1.11, 95% CI 1.05–1.17; p < 0.001) and a greater proportion of supratherapeutic days (HR 1.06, 95% CI 1.02–1.10; p = 0.005) were also associated with AKI. Conclusion: Early AKI in HCT recipients is strongly associated with baseline clinical vulnerability, hepatic dysfunction, and calcineurin inhibitor exposure. Elevated AST and lower albumin levels identify patients at increased risk, while higher cyclosporine exposure contributes to early renal injury. In contrast, transplant‐related characteristics show limited independent influence. These findings support early risk stratification, careful therapeutic monitoring, and individualized immunosuppression to reduce renal complications during the initial post‐HCT period.


  • Open Access

    The Brazilian Data Managers Working Group: a 10-year grassroots initiative for the development of the national hematopoietic cell transplantation and cellular therapy registry

    by Cinthya Corrêa da Silva, Heliz Regina Alves das Neves, Anderson João Simione, Alayne Magalhães Trindade Domingues Yamada, Antonio Vaz de Macedo, Afonso Celso Vigorito, Vanessa Aparecida Do Nascimento Varjão, Flavia Ferreira da Costa, Adriana Mendes de Quadros Cavilha, Monique Ammi, et al.

    Hematopoietic cell transplantation is a data-driven field, and reporting to outcomes registries has become a common practice worldwide. However, comprehensive transplant data collection requires dedicated professionals who can accurately capture data, follow international guidelines, and maintain reliable databases for the evaluation of transplant outcomes. This article describes the development and evolution of the Brazilian Data Managers Working Group (GTGD) and its contributions to professional education, collaborative networking, registry implementation, data quality improvement, and scientific engagement in hematopoietic cell transplantation and cellular therapy in Brazil. The transition from single-center reporting to the establishment of a national transplant registry required collaboration among centers, partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR), and the development of the GTGD to ensure the sustainability of this effort. The GTGD originated from a grassroots collaboration among data managers and transplant centers seeking to address limited professional recognition, inconsistent reporting practices, and restricted access to specialized training. Supported by collaboration with the SBTMO and CIBMTR, the initiative evolved into a nationally coordinated network. Over the decade, the GTGD promoted structured education, knowledge sharing, professional development, operational support, standardized data-management practices, quality-improvement initiatives, and scientific collaboration. In parallel, participation in the national multicenter protocol expanded to 95 centers, with 51 centers reporting data to the CIBMTR by 2025. The group also developed educational resources, supported benchmarking and cellular therapy reporting, strengthened national and international collaboration, and increased the visibility and professional identity of data managers within transplant programs. This experience demonstrates how coordinated engagement, continuous education, institutional collaboration, and professional advocacy can contribute to the development of national registry infrastructure and the generation of reliable real-world evidence in hematopoietic cell transplantation and cellular therapy.

  • Open Access

    Impacto da implantação do inventário rotativo diário na acurácia do estoque de medicamentos em um hospital público de médio porte

    by Luiz Carlos Costa-Junior, Gabriel Gouveia Clemente, Bruna Santuzzi Tebaldi, Sabrina Gomes Andrade, Juliana Tinoco Saldanha, Priscila Ribeiro, Geisy de Carvalho Alcantara, Luciane Christina Silva, Marlon Silveira Machado-Gomes, Melissa Diniz Salgado, et al.

    Objetivo: Avaliar o impacto da implantação do inventário rotativo diário na acurácia do estoque de medicamentos em um hospital público de médio porte. Metodologia: Trata-se de um estudo descritivo exploratório transversal que avaliou a implantação de um inventário rotativo de janeiro a julho de 2022. Foram selecionados 143 medicamentos que posteriormente foram inventariados, uma vez por mês, ao longo de sete meses. Esses medicamentos foram classificados segundo a curva ABC, XYZ e o grau de divergência em: baixo, médio e alto. Foi calculada a acurácia para cada grupo, ao longo dos meses analisados, e o Percentual de Mudança Relativa (PMR) para comparação entre o período inicial e final. Resultado: Houve um aumento de 64% na acurácia do estoque de medicamentos, sendo observada diferença entre os grupos ABC e XYZ. Em relação a curva ABC, o grupo A teve um aumento de 170%, o B de 358% e o C de 23% no mesmo período. Em relação a criticidade, o grupo Z foi o que teve maior acurácia, seguido dos grupos Y e X. Os medicamentos classificados como de alta taxa de divergência tiveram redução de 80% e o de baixa 25% após implantação do inventário. Conclusão: A implantação do inventário rotativo aumentou a acurácia do estoque de medicamentos ao longo dos meses avaliados. Essa ferramenta pode ser uma estratégia utilizada na melhoria do gerenciamento de estoque de medicamentos.


  • Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers

    by Clarissa Lourenço de Castro, Luiz Carlos da Costa Junior, Letícia Vieira Lourenço, Karine Souza Seba, Taiana Sousa Lopes da Silva, Rosane Vianna-Jorge

    Gynecologic malignancies are often detected in advanced stages, requiring chemotherapy with taxane/platinum combinations, which may cause severe toxicities, such as neutropenia and peripheral neuropathy. Gene polymorphisms are suspected as possible causes for the interindividual variability on chemotherapy toxicities.